Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

Fig. 1

Ex vivo treatment with apabetalone (Apa) abolishes pro-inflammatory protein secretion in monocytes isolated from DM2 + CVD patients. a Flow cytometry analysis of the pro-inflammatory surface receptor TLR2 in DM2 + CVD versus control monocytes. b Quantification of secreted cytokines 24 h post-plating (Milliplex®) in DMSO or apabetalone (25 μM)-treated control and DM2 + CVD monocytes. c Effect of apabetalone (25 μM) treatment on secretion of key pro- and anti-inflammatory cytokines in DM2 + CVD monocytes. Statistics: a Unpaired Student’s t-test, *p < 0.05; ns, non-significant. b, c 2-Way repeated measures ANOVA followed by Tukey’s multiple comparisons correction for within-group comparisons, or Bonferroni’s test for between-group comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Individual patient data are shown as a mean ± SEM

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us